dc.contributor.author | Gokani, B | en_US |
dc.contributor.author | Sacoor, S | en_US |
dc.contributor.author | Leisegang, GR | en_US |
dc.contributor.author | Ogunkolade, W | en_US |
dc.contributor.author | Bibi, A | en_US |
dc.contributor.author | Grigoriadou, S | en_US |
dc.contributor.author | Pade, C | en_US |
dc.contributor.author | Gibbons, J | en_US |
dc.contributor.author | Senusi, A | en_US |
dc.contributor.author | Fortune, F | en_US |
dc.date.accessioned | 2024-02-14T09:55:08Z | |
dc.date.available | 2023-07-18 | en_US |
dc.date.issued | 2023 | en_US |
dc.identifier.issn | 1521-6616 | en_US |
dc.identifier.other | ARTN 109700 | |
dc.identifier.other | ARTN 109700 | |
dc.identifier.other | ARTN 109700 | en_US |
dc.identifier.other | ARTN 109700 | en_US |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/94626 | |
dc.relation.ispartof | CLINICAL IMMUNOLOGY | en_US |
dc.subject | Behcet's disease response | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.subject | COVID-19 vaccines | en_US |
dc.subject | Anti -spike IgG | en_US |
dc.subject | Nucleocapsid IgG | en_US |
dc.subject | Immunosuppressive medication | en_US |
dc.title | Behcet's patients' response to COVID-19 vaccination | en_US |
dc.type | Article | |
dc.rights.holder | 2023 Elsevier Inc. All rights reserved. | |
dc.identifier.doi | 10.1016/j.clim.2023.109700 | en_US |
pubs.author-url | https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:001052206100001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 255 | en_US |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |
qmul.funder | Towards drug development: mechanistic insight into REAF/TASOR restriction and Vpr mediated counter-restriction.::Barts Charity | en_US |
qmul.funder | Towards drug development: mechanistic insight into REAF/TASOR restriction and Vpr mediated counter-restriction.::Barts Charity | en_US |